Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Institution	Shares	Value	Change
Johnson & Johnson	5,623,816	$212M	UNCHANGED
Morgan Stanley	49,789	$2M	INCREASED
Jane Street Group	32,180	$1M	NEW
Hrt Financial	27,332	$1M	NEW
Xtx Topco	15,855	$598K	NEW

Nanobiotix S.A. American Depositary Shares (NBTX) Ownership & Trading Activity

Top Institutional Holders